#Veterans Affairs

The VA has cured HCV in nearly 100,000 veterans, which will dramatically reduce the development of advanced liver disease and liver cancer.

A study of veterans also found, as other studies have, that treating the virus helps mitigate the risk of cardiovascular disease.

Direct-acting antivirals lower the risk of cardiovascular disease to a greater extent than interferon-based regimens.

Direct-acting antivirals lower this risk to a greater extent than interferon-based regimens.

This is according to an analysis of a large group of veterans.

Although the program was small, researchers are encouraged by the high success rate in reaching this vulnerable population.

More than 125,000 veterans will have received lifesaving cures by October 2018.

Memorial Day: Remembering our veterans with hepatitis C

Cure rates were near 100 percent even though the population in the study’s analysis had high rates of other health conditions.

The agency will have treated more than 125,000 veterans since it started offering next-generation treatments in 2014.

Use of drugs like Nexium or Prilosec is tied to progression to cirrhosis, decompensated cirrhosis and liver cancer in this population.

A look at U.S. military veterans who have hepatitis C.

Merck’s hepatitis C treatment cured almost all those with stages 3 through 5 of chronic kidney disease in a VA database.

The company has partnered with the American Liver Foundation to host a series of veteran-specific education workshops across the country.

Making a difference in California, one person at a time.